A Review of Guselkumab, an IL-23 Inhibitor, for Moderate-to-Severe Plaque Psoriasis

Z Nawas; M Hatch; E Ramos; M Liu; Y Tong; A Peranteau; S Tyring

A Review of Guselkumab, an IL-23 Inhibitor, for Moderate-to-Severe Plaque Psoriasis

Skin Therapy Lett. 2017 Mar;22(2):8-10.

Authors

Z Nawas¹, M Hatch², E Ramos¹, M Liu³, Y Tong⁴, A Peranteau⁴, S Tyring⁵

Affiliations

¹ Center For Clinical Studies, Houston, TX, USA.
² Texas Tech School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
³ Baylor College of Medicine, Houston, TX, USA.
⁴ Center For Clinical Studies, Houston, TX, USA; Department of Dermatology, University of California San Diego, La Jolla, CA, USA.
⁵ Department of Dermatology, University of Texas Health Science Center, Houston, TX, USA.

PMID: 28329405

Abstract

Psoriasis is a chronic inflammatory skin disorder that affects 2% of the population. Evidence suggests that interleukin (IL)-23 plays a pivotal role in the pathogenesis of psoriasis. Guselkumab is a subcutaneously administered, humanized anti-IL23 monoclonal antibody indicated for the treatment of moderate-to-severe plaque psoriasis. Data from Phase I-III trials in this patient population reveal that guselkumab has proven to be superior to placebo or adalimumab based on achieving a Psoriasis Area and Severity Index (PASI) 90% reduction, or a static Physician Global Assessment (sPGA) score of 0 or 1 from baseline. This article reviews the current status of guselkumab as a therapy for moderate-to-severe plaque psoriasis.

Publication types

Review

MeSH terms

Antibodies, Monoclonal / administration & dosage
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Clinical Trials as Topic
Humans
Interleukin-23 / antagonists & inhibitors*
Psoriasis / drug therapy*
Psoriasis / pathology
Severity of Illness Index

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Interleukin-23
guselkumab